Skip to content

PolitiKit

Lobbying by Bayer Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Bayer Inc.

Meetings this Parliament
17
With MPs
4
Since Nov 2021
27
Active registrations
1

Most recent reported meeting: Sep 29, 2026.

Registrations in effect

In-house (corporation) In effect since Oct 1, 2026

Filed by Viktoria Friedrich, Country President and General Manager - Pharmaceutical Division

Lobbyists

  • Adrian Kupesic · Director, Public and Government Affairs
  • Brandon Levac · Head, Market Access and Government Affairs
  • Shurjeel Choudhri · Head, Medical & Scientific Affairs
  • Viktoria Friedrich · Country President and General Manager - Pharmaceutical Division

Institutions they may lobby: Canada Revenue Agency (CRA), Canadian Food Inspection Agency (CFIA), Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Invest in Canada Hub, National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (5)
  • Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
  • Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.
  • Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
  • Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada
  • Communicating with government officials on Bill S-243, An Act to establish a national framework for women’s health in Canada. Providing guidance, subject matter expertise and relevant information to help inform future policy development.

Registration 955828-4969-34. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Viktoria Friedrich (21), Alok Kanti (6).

  • Reported by Alok Kanti · In-house (corporation)

    • Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    HealthIndustryIntellectual PropertyScience and Technology

    Official report

  • Reported by Alok Kanti · In-house (corporation)

    • Stephan Lucas · Deputy Minister, Health Canada (HC)
    • Nancy Hamzawi · Assistant Deputy Minister, Health Canada (HC)

    HealthIndustryIntellectual PropertyInternational TradeScience and Technology

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.